Lixte Biotechnology Holdings Inc - Company Profile
Powered by 
All the data and insights you need on Lixte Biotechnology Holdings Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Lixte Biotechnology Holdings Inc Strategy Report
- Understand Lixte Biotechnology Holdings Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Lixte Biotechnology Holdings Inc (Lixte) is a drug discovery company, which focuses on the discovery and development of novel drugs for the treatment of cancer and non-cancer diseases using its biomarker technology. It develops two classes of drugs, namely, protein phosphatase inhibitors (PTase-i) designated as the LB-100 series; and histone deacetylase inhibitors (HDACi), designated as the LB-200 series of compounds. The company’s product pipeline comprises drug candidates for the treatment of cancer and neurodegenerative disorders such as small lung cancer, soft tissue sarcoma, myelodysplastic syndrome, and glimos among others. Lixte primarly operates in the US and has collaborations with academic centers, contract research organizations and pharmaceutical companies for development of its anti-cancer treatments. Lixte is headquartered in New York, the US.
Headquarters
United States of America
Address
No. 2, 248 Route 25a, East Setauket, New York, 11733
Website
lixte.com
Telephone
1 310 2032902
No of Employees
3
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
LIXT (NASD)
EPS
XYZ
Net Income (2022)
XYZ
6.2%
(2022 vs 2021)
Market Cap*
$7.2M
Net Profit Margin (0 vs)
XYZ
0.0%
(2022 vs 2021)
* As of and is in US$
Lixte Biotechnology Holdings Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| LB-100 Series |
| Myelodysplastic Syndromes (MDS) |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Lixte Biotechnology Holdings Inc | Xenetic Biosciences Inc | Aptose Biosciences Inc | Ariad Pharmaceuticals Inc | Array BioPharma Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Canada | United States of America | United States of America |
| City | East Setauket | Framingham | North York | Cambridge | Boulder |
| State/Province | New York | Massachusetts | Ontario | Massachusetts | Colorado |
| No. of Employees | 3 | 4 | 35 | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| John S. Kovach, M.D. | Chief Scientific Officer; Chairman | Executive Board | 2023 | - |
| Bas van der Baan | Chief Executive Officer; President; Vice Chairman | Executive Board | 2023 | - |
| Robert N. Weingarten | Vice President; Chief Financial Officer | Senior Management | 2020 | 70 |
| Eric J. Forman | Vice President; Chief Operating Officer | Senior Management | 2022 | 42 |
| James Miser | Chief Medical Officer | Senior Management | 2020 | 75 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer